Iris Acquisition CORP Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Iris Acquisition Corp has filed an amendment to its registration statement related to the proposed business combination with Liminatus Pharma.
Iris Acquisition Corp has filed an amendment to its registration statement related to its proposed business combination with Liminatus Pharma.
Iris Acquisition Corp has filed an amendment to its registration statement related to the proposed business combination with Liminatus Pharma.
Iris Acquisition Corp. and Liminatus Pharma have amended their business combination agreement for the sixth time, significantly reducing the enterprise value of Liminatus to $175 million.
Iris Acquisition Corp has filed an amendment to its registration statement related to the proposed business combination with Liminatus Pharma.
Iris Acquisition Corp has filed an amendment to its registration statement related to the proposed business combination with Liminatus Pharma.
Iris Acquisition Corp. announces a fourth amendment to its business combination agreement with Liminatus Pharma, extending the deadline to September 3, 2024, and adjusts the PIPE equity subscription while terminating the convertible note subscription.